The importance of antiangiogenic effect in multiple myeloma treatment.

Abstract

Angiogenesis plays a significant role in oncogenesis, and thus it has become an attractive target for cancer treatment. It is the formation of new blood vessels that occurs physiologically as well as under pathological conditions, and may influence cancer proliferation and survival. The current therapeutic approach in oncology includes conventional chemotherapy in combination with biologically-based treatment in various perspectives, targeting not only the malignant cells, but also its microenvironment. Target treatment might be less toxic than conventional chemotherapy. In multiple myeloma, there is a close connection between bone marrow stroma, myeloma cell growth and their ability to survive. It has been reported in many clinical observations that the more advanced the multiple myeloma, the more increased the angiogenesis, and this might correlate with the treatment response. There are several angiogenesis inhibitors already registered or in clinical trials in cancer treatment. Despite the continuous research on the development of prognostic factors and introduction of new agents in the treatment, multiple myeloma still remains an incurable and debilitating disease. Some antiangiogenic agents have already been introduced in multiple myeloma treatment, but there is still a need to search for new antiangiogenic drugs and the exploitation of angiogenesis in a clinical approach.